PDGFRB and neoplasm: In a murine B16-OVA melanoma model, combination therapy with dasatinib – a RTK inhibitor targeting BCR-ABL, SRC, c-KIT, and PDGFR – and OVA-pulsed DC1 vaccines decreased TME levels of MDSCs and Treg, enhanced TME recruitment of IL12p70-producing DC1, and promoted a profound spreading in the repertoire of tumor-associated antigens recognized by CD8+ TILs (63).